🧠 LSD for anxiety
A new trial tested a single dose of LSD (MM120) for adults with anxiety. The 100 µg dose worked best at easing symptoms. Larger trials are next.
🔗 doi.org/10.1001/jama...
#SciComm 🧪 #LSD
A new trial tested a single dose of LSD (MM120) for adults with anxiety. The 100 µg dose worked best at easing symptoms. Larger trials are next.
🔗 doi.org/10.1001/jama...
#SciComm 🧪 #LSD
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
This randomized clinical trial assesses the dose-response relationship of MM120 (lysergide D-tartrate) vs placebo in adults with moderate to severe generalized anxiety disorder.
doi.org
September 6, 2025 at 6:58 AM
🧠 LSD for anxiety
A new trial tested a single dose of LSD (MM120) for adults with anxiety. The 100 µg dose worked best at easing symptoms. Larger trials are next.
🔗 doi.org/10.1001/jama...
#SciComm 🧪 #LSD
A new trial tested a single dose of LSD (MM120) for adults with anxiety. The 100 µg dose worked best at easing symptoms. Larger trials are next.
🔗 doi.org/10.1001/jama...
#SciComm 🧪 #LSD
In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety.
ja.ma/4g846la
ja.ma/4g846la
September 4, 2025 at 4:00 PM
In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety.
ja.ma/4g846la
ja.ma/4g846la
A single dose of MM120, a pharmaceutical-grade LSD compound, could mark a breakthrough in treating generalized anxiety disorder (GAD), according to a new phase 2b clinical trial published in JAMA.
#LSDTherapy #AnxietyTreatment #MentalHealth #Neuroplasticity #MM120 #Psychiatry
#LSDTherapy #AnxietyTreatment #MentalHealth #Neuroplasticity #MM120 #Psychiatry
September 20, 2025 at 3:46 PM
A single dose of MM120, a pharmaceutical-grade LSD compound, could mark a breakthrough in treating generalized anxiety disorder (GAD), according to a new phase 2b clinical trial published in JAMA.
#LSDTherapy #AnxietyTreatment #MentalHealth #Neuroplasticity #MM120 #Psychiatry
#LSDTherapy #AnxietyTreatment #MentalHealth #Neuroplasticity #MM120 #Psychiatry
In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety. 🧵
ja.ma/4qlPkMz
ja.ma/4qlPkMz
October 21, 2025 at 4:08 PM
In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety. 🧵
ja.ma/4qlPkMz
ja.ma/4qlPkMz
From my collection, unpublished/rejected letters to the editor, which I share as preprints, because I think the conversation is important
LSD for generalized anxiety disorder trial in @jama.com
jamanetwork.com/journals/jam...
Our letter: osf.io/preprints/ps...
LSD for generalized anxiety disorder trial in @jama.com
jamanetwork.com/journals/jam...
Our letter: osf.io/preprints/ps...
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
This randomized clinical trial assesses the dose-response relationship of MM120 (lysergide D-tartrate) vs placebo in adults with moderate to severe generalized anxiety disorder.
jamanetwork.com
March 12, 2026 at 2:07 PM
From my collection, unpublished/rejected letters to the editor, which I share as preprints, because I think the conversation is important
LSD for generalized anxiety disorder trial in @jama.com
jamanetwork.com/journals/jam...
Our letter: osf.io/preprints/ps...
LSD for generalized anxiety disorder trial in @jama.com
jamanetwork.com/journals/jam...
Our letter: osf.io/preprints/ps...
1/15 💊 BREAKTHROUGH: SINGLE LSD DOSE SHOWS LASTING ANXIETY RELIEF 💊
JAMA publishes first phase 2b trial of MM120 (pharmaceutical LSD) for generalised anxiety disorder. Single treatment reduced symptoms for up to 12 weeks.
Major mental health advance.
#LSDResearch #AnxietyTreatment #Anxiety #GAD
JAMA publishes first phase 2b trial of MM120 (pharmaceutical LSD) for generalised anxiety disorder. Single treatment reduced symptoms for up to 12 weeks.
Major mental health advance.
#LSDResearch #AnxietyTreatment #Anxiety #GAD
September 4, 2025 at 9:21 PM
1/15 💊 BREAKTHROUGH: SINGLE LSD DOSE SHOWS LASTING ANXIETY RELIEF 💊
JAMA publishes first phase 2b trial of MM120 (pharmaceutical LSD) for generalised anxiety disorder. Single treatment reduced symptoms for up to 12 weeks.
Major mental health advance.
#LSDResearch #AnxietyTreatment #Anxiety #GAD
JAMA publishes first phase 2b trial of MM120 (pharmaceutical LSD) for generalised anxiety disorder. Single treatment reduced symptoms for up to 12 weeks.
Major mental health advance.
#LSDResearch #AnxietyTreatment #Anxiety #GAD
#mentalhealth #PsychedelicInspiredMedicine #MindMed #MM120 #anxietydisorder #GeneralisedAnxietyDisorder #GAD #GADtreatment #MM120ODT #lysergideDtartrate #LSD #clinicaltrialparticipants #Voyagestudy #GADpatients #BreakthroughTherapyDesignation #Panoramastudy
pharmatimes.com/news/mindmed...
pharmatimes.com/news/mindmed...
MindMed begins phase 3 study of MM120 for anxiety disorder - PharmaTimes
First patient dosed in landmark trial for GAD treatment
pharmatimes.com
December 19, 2024 at 11:53 AM
Single doses of MM120 reduce anxiety in GAD patients; significant effects seen with 100 and 200 µg, but not 25 or 50 µg.
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
October 30, 2025 at 2:35 PM
Single doses of MM120 reduce anxiety in GAD patients; significant effects seen with 100 and 200 µg, but not 25 or 50 µg.
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
MindMed is developing MM120, the tartrate salt form of lysergide, for GAD and MDD and is exploring its potential applications in other serious brain health disorders. MM120 (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic psychedelics.
MindMed.co
MindMed.co
November 10, 2024 at 3:01 PM
MindMed is developing MM120, the tartrate salt form of lysergide, for GAD and MDD and is exploring its potential applications in other serious brain health disorders. MM120 (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic psychedelics.
MindMed.co
MindMed.co
MindMed Doses First Patient in LSD Anxiety Treatment Trial
Video: youtube.com/shorts/Ewhvi...
#MNMD #MNMDStock #MindMed #MindMedStock #LSDTreatment #MM120 #PsychedelicTreatment #Anxiety #AnxietyTreatment #AnxietyPsychedelics #PsychedelicsAnxiety #LSDAnxietyTreatment #MindMedVoyager
Video: youtube.com/shorts/Ewhvi...
#MNMD #MNMDStock #MindMed #MindMedStock #LSDTreatment #MM120 #PsychedelicTreatment #Anxiety #AnxietyTreatment #AnxietyPsychedelics #PsychedelicsAnxiety #LSDAnxietyTreatment #MindMedVoyager
December 17, 2024 at 5:00 PM
MindMed Doses First Patient in LSD Anxiety Treatment Trial
Video: youtube.com/shorts/Ewhvi...
#MNMD #MNMDStock #MindMed #MindMedStock #LSDTreatment #MM120 #PsychedelicTreatment #Anxiety #AnxietyTreatment #AnxietyPsychedelics #PsychedelicsAnxiety #LSDAnxietyTreatment #MindMedVoyager
Video: youtube.com/shorts/Ewhvi...
#MNMD #MNMDStock #MindMed #MindMedStock #LSDTreatment #MM120 #PsychedelicTreatment #Anxiety #AnxietyTreatment #AnxietyPsychedelics #PsychedelicsAnxiety #LSDAnxietyTreatment #MindMedVoyager
コンサータみたいに処方が厳密に管理されそう。
> 臨床試験に使ったＭＭ１２０は、禁止薬物として出回っているＬＳＤと違って「バッドトリップ（不快な幻覚作用）」を引き起こさないとカーリン氏は説明。「ＬＳＤは純度の高い製造が難しく、光や水で瞬く間に劣化する傾向がある」「我々はこれを医薬品業界の基準に従って製造し、純度と安定性を高めた。これは決定的な違いだ」と強調する。
> 臨床試験に使ったＭＭ１２０は、禁止薬物として出回っているＬＳＤと違って「バッドトリップ（不快な幻覚作用）」を引き起こさないとカーリン氏は説明。「ＬＳＤは純度の高い製造が難しく、光や水で瞬く間に劣化する傾向がある」「我々はこれを医薬品業界の基準に従って製造し、純度と安定性を高めた。これは決定的な違いだ」と強調する。
不安障害の患者にＬＳＤ投与、１回で即効性と持続性確認 ＦＤＡが「画期的治療薬」に指定
バイオ医薬品会社のマインド・メディシンは７日、合成麻薬ＬＳＤを使った全般性不安障害の治療薬「ＭＭ１２０」について、臨床試験で有望な結果が出たことを受け、米食品医薬品局（ＦＤＡ）の画期的治療薬（ブレークスルー治療薬）に指定されたと発表した。 - (1/2)
www.cnn.co.jp
March 9, 2024 at 5:43 AM
コンサータみたいに処方が厳密に管理されそう。
> 臨床試験に使ったＭＭ１２０は、禁止薬物として出回っているＬＳＤと違って「バッドトリップ（不快な幻覚作用）」を引き起こさないとカーリン氏は説明。「ＬＳＤは純度の高い製造が難しく、光や水で瞬く間に劣化する傾向がある」「我々はこれを医薬品業界の基準に従って製造し、純度と安定性を高めた。これは決定的な違いだ」と強調する。
> 臨床試験に使ったＭＭ１２０は、禁止薬物として出回っているＬＳＤと違って「バッドトリップ（不快な幻覚作用）」を引き起こさないとカーリン氏は説明。「ＬＳＤは純度の高い製造が難しく、光や水で瞬く間に劣化する傾向がある」「我々はこれを医薬品業界の基準に従って製造し、純度と安定性を高めた。これは決定的な違いだ」と強調する。
Un estudio revela que una sola dosis de MM120, derivado del LSD, podría reducir la ansiedad generalizada durante semanas. Resultados prometedores y efectos leves abren nuevas posibilidades en tratamientos con compuestos psicodélicos.
DOI: 10.1001/jama.2025.13481
cerebrodigital.net/lsd-trat...
DOI: 10.1001/jama.2025.13481
cerebrodigital.net/lsd-trat...
Ansiedad generalizada: una sola dosis de LSD podría revolucionar su tratamiento
El trastorno de ansiedad generalizada (GAD) afecta a millones de personas y suele tratarse con fármacos que requieren el uso diario y pueden causar dependencia o efectos secundarios molestos.
cerebrodigital.net
September 21, 2025 at 2:59 AM
Un estudio revela que una sola dosis de MM120, derivado del LSD, podría reducir la ansiedad generalizada durante semanas. Resultados prometedores y efectos leves abren nuevas posibilidades en tratamientos con compuestos psicodélicos.
DOI: 10.1001/jama.2025.13481
cerebrodigital.net/lsd-trat...
DOI: 10.1001/jama.2025.13481
cerebrodigital.net/lsd-trat...
Abstract 🧠👉🏼 pubmed.ncbi.nlm.nih.gov/40906494/
“MM120 is a derivative of LSD, acting as a partial agonist at serotonin-2A receptors, suggesting a novel mechanism of action for anxiety treatment…” 👉🏼 hcn.health/hcn-trends-s...
#supportresearch
#supportscience 🤓
“MM120 is a derivative of LSD, acting as a partial agonist at serotonin-2A receptors, suggesting a novel mechanism of action for anxiety treatment…” 👉🏼 hcn.health/hcn-trends-s...
#supportresearch
#supportscience 🤓
September 5, 2025 at 3:05 PM
Abstract 🧠👉🏼 pubmed.ncbi.nlm.nih.gov/40906494/
“MM120 is a derivative of LSD, acting as a partial agonist at serotonin-2A receptors, suggesting a novel mechanism of action for anxiety treatment…” 👉🏼 hcn.health/hcn-trends-s...
#supportresearch
#supportscience 🤓
“MM120 is a derivative of LSD, acting as a partial agonist at serotonin-2A receptors, suggesting a novel mechanism of action for anxiety treatment…” 👉🏼 hcn.health/hcn-trends-s...
#supportresearch
#supportscience 🤓
マツエク、カールいちばん強め13mm120本でお願いしたけれど、もうちょい本数増やさないと取れちゃってみずぼらしくみえるな
October 24, 2025 at 10:50 AM
マツエク、カールいちばん強め13mm120本でお願いしたけれど、もうちょい本数増やさないと取れちゃってみずぼらしくみえるな
2/15 The rigorous double-blind, placebo-controlled study enrolled 198 adults with moderate to severe GAD across 22 US research sites.
Participants received single doses of 25μg, 50μg, 100μg, 200μg MM120, or placebo. Results were assessed by independent raters.
#ClinicalTrial #GAD
Participants received single doses of 25μg, 50μg, 100μg, 200μg MM120, or placebo. Results were assessed by independent raters.
#ClinicalTrial #GAD
September 4, 2025 at 9:22 PM
2/15 The rigorous double-blind, placebo-controlled study enrolled 198 adults with moderate to severe GAD across 22 US research sites.
Participants received single doses of 25μg, 50μg, 100μg, 200μg MM120, or placebo. Results were assessed by independent raters.
#ClinicalTrial #GAD
Participants received single doses of 25μg, 50μg, 100μg, 200μg MM120, or placebo. Results were assessed by independent raters.
#ClinicalTrial #GAD
Single doses of MM120 significantly reduce anxiety in patients with moderate to severe GAD, especially at 100 and 200 µg levels.
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
September 13, 2025 at 12:49 PM
Single doses of MM120 significantly reduce anxiety in patients with moderate to severe GAD, especially at 100 and 200 µg levels.
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
by Robison R, Barrow R (...) Fava M et 9 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2838505
sounds like a promising medication that needs better name #samokažem
m.ca.investing.com/news/stock-m...
m.ca.investing.com/news/stock-m...
MindMed's MM120 shows promise in GAD treatment By Investing.com
MindMed's MM120 shows promise in GAD treatment
m.ca.investing.com
March 8, 2024 at 11:51 AM
sounds like a promising medication that needs better name #samokažem
m.ca.investing.com/news/stock-m...
m.ca.investing.com/news/stock-m...
📌 Editor’s Choice from this week's issue of #JAMA:
➡️ Remote Screening for Asymptomatic AFib
➡️ Single-Dose MM120 (Lysergide) for Anxiety
➡️ Review of Early-Onset GI Cancers, and more.
ja.ma/4eRp9GH
➡️ Remote Screening for Asymptomatic AFib
➡️ Single-Dose MM120 (Lysergide) for Anxiety
➡️ Review of Early-Onset GI Cancers, and more.
ja.ma/4eRp9GH
October 21, 2025 at 5:00 PM
📌 Editor’s Choice from this week's issue of #JAMA:
➡️ Remote Screening for Asymptomatic AFib
➡️ Single-Dose MM120 (Lysergide) for Anxiety
➡️ Review of Early-Onset GI Cancers, and more.
ja.ma/4eRp9GH
➡️ Remote Screening for Asymptomatic AFib
➡️ Single-Dose MM120 (Lysergide) for Anxiety
➡️ Review of Early-Onset GI Cancers, and more.
ja.ma/4eRp9GH
MM120, a pharmaceutical form of LSD, shown to reduce anxiety symptoms (2025) (www.sciencedaily.com)
Discussion | Main Link
Discussion | Main Link
March 16, 2026 at 6:27 PM
MM120, a pharmaceutical form of LSD, shown to reduce anxiety symptoms (2025) (www.sciencedaily.com)
Discussion | Main Link
Discussion | Main Link
www.linkedin.com/pulse/mindme...
MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment
kstrategyand.com
#InnovationPassport #MindMed #MM120 #GeneralizedAnxietyDisorder #GAD #MentalHealthInnovation #HealthcareInnovation #Humanteconomy #Humantec #KStrategyand
MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment
kstrategyand.com
#InnovationPassport #MindMed #MM120 #GeneralizedAnxietyDisorder #GAD #MentalHealthInnovation #HealthcareInnovation #Humanteconomy #Humantec #KStrategyand
MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment
Mind Medicine Inc. (MindMed), a clinical-stage biopharmaceutical company, has achieved a significant milestone with the Innovation Passport designation granted by the United Kingdom’s Innovative Licen...
www.linkedin.com
December 19, 2024 at 10:52 AM
www.linkedin.com/pulse/mindme...
MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment
kstrategyand.com
#InnovationPassport #MindMed #MM120 #GeneralizedAnxietyDisorder #GAD #MentalHealthInnovation #HealthcareInnovation #Humanteconomy #Humantec #KStrategyand
MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment
kstrategyand.com
#InnovationPassport #MindMed #MM120 #GeneralizedAnxietyDisorder #GAD #MentalHealthInnovation #HealthcareInnovation #Humanteconomy #Humantec #KStrategyand
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) - Yahoo… https://news.google....
July 17, 2024 at 11:10 AM
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) - Yahoo… https://news.google....
10/15 The mechanism likely involves increased neuroplasticity in brain regions including the prefrontal cortex.
MM120 acts on 5-HT2A receptors, potentially creating lasting neural changes that explain prolonged therapeutic effects after acute drug clearance.
#Mechanism #Neuroplasticity
MM120 acts on 5-HT2A receptors, potentially creating lasting neural changes that explain prolonged therapeutic effects after acute drug clearance.
#Mechanism #Neuroplasticity
September 4, 2025 at 9:26 PM
10/15 The mechanism likely involves increased neuroplasticity in brain regions including the prefrontal cortex.
MM120 acts on 5-HT2A receptors, potentially creating lasting neural changes that explain prolonged therapeutic effects after acute drug clearance.
#Mechanism #Neuroplasticity
MM120 acts on 5-HT2A receptors, potentially creating lasting neural changes that explain prolonged therapeutic effects after acute drug clearance.
#Mechanism #Neuroplasticity
9/15 Beyond anxiety, MM120 improved depression scores and clinical global impression ratings.
65% of 100μg participants achieved 50% anxiety reduction vs 31% placebo. Remission rates were 47.5% vs 20.5% respectively - unprecedented for single-dose treatment.
#Depression #Remission
65% of 100μg participants achieved 50% anxiety reduction vs 31% placebo. Remission rates were 47.5% vs 20.5% respectively - unprecedented for single-dose treatment.
#Depression #Remission
September 4, 2025 at 9:26 PM
9/15 Beyond anxiety, MM120 improved depression scores and clinical global impression ratings.
65% of 100μg participants achieved 50% anxiety reduction vs 31% placebo. Remission rates were 47.5% vs 20.5% respectively - unprecedented for single-dose treatment.
#Depression #Remission
65% of 100μg participants achieved 50% anxiety reduction vs 31% placebo. Remission rates were 47.5% vs 20.5% respectively - unprecedented for single-dose treatment.
#Depression #Remission